AvenCell Therapeutics

Expanding The CAR-T Market From $6B To $30B

About this Event

AvenCell Therapeutics is pioneering the next generation of cancer treatment with powerful, persistent, and switchable allogeneic CAR-T therapies made from healthy donor cells that perform as well or better than a patient’s own.

Traditional CAR-T therapies have transformed outcomes for some patients but remain limited by high cost, long manufacturing times, and patient-specific production. AvenCell’s proprietary gene-editing and switchable receptor technologies overcome these barriers, enabling scalable, stockpiled, and more potent off-the-shelf treatments at a fraction of current costs.

The company’s two lead programs target billion-dollar markets:
  • AVC-201: a switchable, CAR-T therapy for Acute Myeloid Leukemia (AML) showing more than 600 times higher cell expansion and early clinical responses in Phase I trials
  • AVC-203: a dual-antigen CAR-T treatment for B-cell lymphomas designed to match or exceed best-in-class autologous therapies, with manufacturing costs that are reduced by at least 90%.

AvenCell has received a $40 million non-dilutive grant from Japan’s AMED agency and strong backing from Blackstone Life Sciences, Novo Holdings, and F-Prime Capital.

Register today to watch our Fireside Chat with AvenCell CEO, Andrew Schiermeier, to hear why the company well positioned to deliver multiple near-term value inflection points and potential strategic exits.

Video On Demand

– Recorded

January 27

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.